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A comprehensive framework for considering 
additional unintended consequences 
in economic evaluation
Liv Nymark1* and Anna Vassall1,2
Abstract 
Background: In recent years there has been a growth in economic evaluations that consider indirect health benefits 
to populations due to advances in mathematical modeling. In addition, economic evaluations guidelines have sug-
gested the inclusion of impact inventories to include non-health direct and indirect consequences. We aim to bring 
together this literature, together with the broader literature on internalities and externalities to propose a comprehen-
sive approach for analysts to identify and characterize all unintended consequences in economic evaluations.
Methods: We present a framework to assist analysts identify and characterize additional costs and effects beyond 
that of direct health impact primarily intended to be influenced by the intervention/technology. We build on previous 
checklists to provide analysts with a comprehensive framework to justify the inclusion or exclusion of effects, support-
ing the use of current guidelines, to ensure any unintended effects are considered. We illustrate this framework with 
examples from immunization. These were identified from a previous systematic review, PhD thesis work, and general 
search scoping in PubMed databases.
Results: We present a comprehensive framework to consider additional consequences, exemplified by types and 
categories. We bring this and other guidance together to assist analysts identify possible unintended consequences 
whether taking a provider or societal perspective.
Conclusions: Although there are many challenges ahead to standardize the inclusion of additional consequences 
in economic evaluation, we hope by moving beyond generic statements to reporting against a comprehensive 
framework of additional effects we can support further consistency in this aspect of cost-effectiveness analysis going 
forward.
Keywords: Cost-effectiveness analysis, Indirect effects, Consequences, Externality, Internality, Guidelines
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Guidelines for performing economic evaluations of 
healthcare interventions have emerged as a tool to sup-
port the quality and standardization of cost-effective-
ness analysis [1–3]. Generally, these guidelines state that 
analysts should consider all relevant direct and indirect 
effects [4, 5], although these may be limited by the payer 
perspective, and often are contained to health effects. 
Some guidelines provide additional guidance on the 
inclusion of non-health effects [6, 7]. For example, the 
Second Panel on Cost-Effectiveness in Health and Medi-
cine defines societal benefits as non-health effects and 
costs which are not accrued to health budgets, and pro-
vides a reporting checklist, known as an ‘impact inven-
tory’ to report these. The checklist includes impacts on 
areas such as educational outcomes. The International 
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Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) has also highlighted the importance of map-
ping indirect health and non-health effects into econom-
ics frameworks for value assessment. The ISPOR Special 
Task Force report states that while indirect effects such 
as labor productivity and adherence improving factors 
are covered to some extent in current cost-effectiveness 
analyses, other categories such as scientific spillover 
effects are virtually absent [8]. Finally, various infectious 
disease-specific guidelines address the inclusion of non-
direct effects, and some (for example, immunization) 
have made also attempts at scoping possible types of 
impact [9–11].
Despite this guidance, it can be challenging for analysts 
to comprehensively map out which non-direct health and 
non-health effects to include in analyses, in addition to 
the primary intended effect [12–14]. As many as two-
thirds of cost-effectiveness studies do not consider how 
to include indirect health effects even when they may 
be substantial [15, 16]. We present here a framework to 
assist analysts identify and characterize additional costs 
and effects beyond that of direct health impact primar-
ily intended to be influenced by the intervention/technol-
ogy. Our aim is not to argue that all these effects should 
be included in every economic evaluation; this should 
depend on the perspective of the evaluation and strength 
of evidence supporting importance of the effect. Instead 
we aim to build on previous checklists to provide analysts 
with a comprehensive framework to justify the inclu-
sion or exclusion of effects, supporting the use of current 
guidelines, to ensure any unintended effects are consid-
ered. We illustrate this framework with examples from 
immunization (see Table  1). These were identified from 
a previous systematic review [15], PhD thesis work [42], 
and general search scoping in PubMed databases.
Methods
Search strategy used to illustrate the framework
The immunization examples used to illustrate the pro-
posed framework were identified from a previous 
review on cost-effectiveness analyses of human vaccines. 
Nymark et al. [15] utilized the following search strategy 
which they limited to English language with free text and 
MeSH terms; vaccin∗, economic evaluat∗, humans.
Other examples of unintended consequences of immu-
nization were identified from a PhD thesis cost-effective-
ness analysis of Bacillus Calmette–Guérin (BCG) versus 
no BCG vaccination for prevention of atopic dermatitis 
in neonates with predisposition to atopic disease [42].
Finally, a search scoping strategy which consisted of 
search terms ‘cost–benefit analysis’ or ‘cost–benefit’ 
and ‘externality’ was utilized to identify any additional 
examples of unintended consequences of immunization 
to illustrate the framework.
Development and validation of the framework
The framework was developed following a review of cur-
rent economic evaluations guidelines [1–11] and reviews 
of the economic evaluation for TB and immunization—in 
which relevant unintended consequences were identi-
fied and classified into different types; biology, demand 
and supply. Unintended consequences were structured 
based on existing frameworks such as the Second Panel 
on Cost-Effectiveness in Health and Medicine and ISPOR 
guidelines and then generalize commonalities among 
secondary effects from these.
Additional unintended consequences were also identi-
fied previous PhD thesis work on immunization [42].
Types and categories of ‘internal’ and ‘external’ person 
consequences
Interventions can have impact beyond the intended 
direct health consequences; such as ‘internal’ conse-
quences (occurring ‘within’ in the individual) and ‘exter-
nal’ consequences (when the reaction occurs ‘outside’ 
the individual). We refer to the former as an ‘internality’ 
and the latter is commonly referred to in economics as an 
externality; defined as a cost or benefit which is caused by 
one person’s action while impacting others who are not 
part of the action [17]. In non-economic literature the 
term externalities is often used interchangeably in refer-
ence to indirect effects, unintended consequences, spillo-
ver effects and non-direct effects.
Depending on perspective, analysts may wish to con-
sider both additional health and non-health conse-
quences. Within health impact, there are several types 
of ‘internalities’ and ‘externalities’ (see Fig. 1). These can 
be divided into biological effects and demand-side and 
supply-side behavioral consequences. The first type ‘bio-
logical’ includes the impact of the intervention on other 
diseases, infection and pathogens. Interventions can 
also impact individual, household and population health 
related consumption; ‘demand-side’ impact. Finally, 
interventions can also impact the supply side, by chang-
ing the behavior of health providers and impacting other 
health services or the provision of non-health services. 
Likewise, there may be internal and external non-health 
consequences demand and supply side impact. Figure  1 
illustrates our framework and we provide further expla-
nation and an example below.
Health sector perspective
Additional biological effects
Biology refers to any chemical, molecular, cellular, 
immune or physiologic process or mechanism which 
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Table 1 Examples of ‘internal’ and ‘external’ person consequences using immunization(s)
Perspective Type ‘Internal’ ‘External’ Example
Health effects Biology Non-specific effects A marked reduced risk of dying from sepsis and 
pneumonia was observed in low-birthweight 
neonates who received BCG immunization at 
birth in an RCT in Guinea-Bissau [22]
Non-specific effects In a Dutch randomized placebo-controlled 
human challenge study BCG vaccination was 
found to induce genome-wide epigenetic 
reprograming of monocytes and protected 
against experimental infection with an attenu-
ated
yellow fever virus vaccine strain [23]
Transmission Marked declines in the diagnoses of genital warts 
in young Australian Aboriginal and Torres Strait 
Islander (Indigenous) men in Australia after the 
introduction of the HPV bivalent vaccination 
programme for females suggests that female 
vaccination offered indirect herd protection for 
men [25]
Pathogen response The change in patterns of serotype replacement 
or shifting causing invasive pneumococcal 
disease (IPD) produced marked declines in 
the incidence of IPD in children and moderate 
declines in adults following the replacement 
of the PCV7 vaccine by the PCV13 vaccine in 
Spain [27]
Pathogen response A comparison of the impact against IPD in PCV10 
and PCV13 vaccinated counties in Sweden 
observed an increase in serotype 6C in PCV10 
counties but not in PCV13 counties. This was 
assumed to indicate that serotype 6A, which 
is included in PCV13 but not in PCV10, offers 
carry-over protective effects against serotype 
6C [28]
Demand-side Change in health behaviour A universal immunization programme in Nepal 
(which aside from providing childhood vaccina-
tions) also educates mothers on vaccination 
has been found to result in positive changes 
in other individual health behaviours, such as 
hygiene and sanitation practices and behav-
iours [34]
Change in health services consumption Following maternal tetanus vaccination in 
Bangladesh the consumption of health care 
services was markedly reduced indicating a 
positive change in the need to seek health care 
services [35]
Supply-side Health Systems Hib vaccination prevents disease and thus 
reduces the need for antibiotic use for treat-
ment which in turn reduces the development 
of antimicrobial resistance (secondary effects) 
[30]
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is activated inside the human body [18]. Central to the 
description of the type biology are the functions and 
mechanisms which work within the human body and 
relate to how organisms, organ systems, cells and mole-
cules carry out their chemical and physical functions and 
how these interactions are regulated, including control 
mechanisms and communication between cells [19]. For 
the type ‘biology’ there are three categories of potential 
additional ‘internal’ and ‘external’ person (host) effects. 
These are: (1) Non-specific effects (NSE) (impacts on 
other diseases); (2) transmission effects (infection to oth-
ers) and (3) pathogen response (impact on the pathogen, 
such as creating new resistant disease).
An example of the first category (NSE) is the case of the 
BCG vaccine is indicated for the prevention of tuberculo-
sis (TB) [20]. NSE of immunization are beneficial effects 
which offer protection beyond specific pathogens [21]. A 
study of BCG immunization at birth in low-birth weight 
neonates (< 2500  g) in Guinea-Bissau found a reduced 
risk of sepsis and pneumonia (non-specific diseases 
which are unrelated to the direct proportion which BCG 
offers against tuberculosis) (see Table  1) [22]. Likewise, 
BCG vaccine has been observed to train the adaptive 
immune response to become more vigilant to subse-
quent vaccinations [23]. Other examples of internal addi-
tional health effects include the impact of anti-retrovirals 
for HIV on the development of active TB from infec-
tion. NSE can be divided into two sub-categories, those 
that have consequence for other diseases and those that 
impact the likelihood of subsequent infections.
The second category, transmission is defined as the 
passing of an infectious agent (pathogen) from an 
infected host individual to another individual. The exter-
nality of transmission is increasing being included in eco-
nomic evaluation of infectious diseases. In addition, the 
transmission of disease from human to human is reduced 
by immunization. Herd immunity is an indirect or ‘exter-
nal’ person effect associated with immunization which 
occurs when unvaccinated (susceptible) individuals avoid 
infectious diseases because a large enough percentage of 
the population who surround them are immunized [24]. 
Thereby providing a measure of indirect protection for 
Table 1 (continued)
Perspective Type ‘Internal’ ‘External’ Example
Non-health effects Demand-side Education PCV vaccination prevents pneumococcal 
pneumonia in children in South Africa. This has 
been associated with children improving their 
educational attainment [9]
Productivity Hib vaccination reduces child mortality. This 
allows mothers of vaccinated children achieve 
their target family size through fewer births. 
This has been shown to result in increased adult 
labour productivity for women [10]
Intra household A study from Belgium suggests that the caregiver 
burden within households in which children 
were not vaccinated against rotavirus was 
markedly severe; especially if no medical care 
was sought [11]
Intra household In Argentina, households have reported negative 
changes in behaviours when a member in the 
household has cervical cancer. This resulted in 
negative impact on educational attainment 
which could have been prevented with the HPV 
vaccination [12]
Supply-side Outside health systems Yearly influenza immunization reduces infection 
and related complications in the elderly and 
therefore result in reduced use of social support 
services outside the health care sector, such as 
social care services [13]
Provider Previously influenza vaccinated healthcare 
providers demonstrated positive behavioural 
changes in their willingness to be vaccinated in 
forthcoming seasons [14]
Italic = internal person (host); bolditalic = external person (host)
PCV Pneumococcal conjugate vaccine, BCG Bacillus Calmette–Guérin, Hib Haemophilus influenzae type b, HPV Human papillomavirus vaccine, RCT Randomized 
Control Trial
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individuals who are not immunized. An example of herd 
immunity is the HPV vaccination programme for females 
in Australia which is associated with declines in the diag-
noses of genital warts in young indigenous men in Aus-
tralia [25]. Hence, vaccinated females not only reduced 
their own direct susceptibility but also reduced the risk 
for unvaccinated males who benefited from a measure of 
indirect herd protection even though they were not the 
direct recipients of the HPV vaccine.
The third category of biology is ‘pathogen response’ 
which refers to the human body’s reaction when an infec-
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Fig. 1 Conceptual framework ‘internal’ and’external’ consequences
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host. The category is classified as an ‘internal’ additional 
effect. In the case of immunization, vaccination can 
result in changes in the underlying serotype of the patho-
gen (in the case of other diseases, incomplete interven-
tion can also result in resistance). Serotype is the term 
used to refer to a group of organisms within a species 
that have the same type and number of surface antigens. 
Antigens are molecules that are capable of stimulating an 
immune response specifically activating the body’s infec-
tion-fighting  white blood cells. Serotype replacement 
is a phenomenon which induces resistance to sub-types 
of serotypes if the frequency of a sub-type of serotype 
declines due to high levels of immunity, allowing other 
serotypes to replace it [26]. Widespread use of pneu-
mococcal conjugate vaccines has been associated with 
serotype replacement or shifting. As demonstrated in 
Navarra, Spain, the incidence of invasive pneumococcal 
disease (IPD) from serotypes not included in the PCV7 
vaccine increased due to resistance following the intro-
duction of this vaccine, which was attributed to serotype 
replacement. However, the incidence of IPD declined, 
and the change in patterns of serotypes causing IPD pro-
duced marked declines in children and moderate declines 
in adults following the replacement of the PCV7 vaccine 
by the PCV13 vaccine [27].
Another potential additional pathogen response is 
cross-protection. Cross-protection is the protection con-
ferred on a host (‘internal’) by infection with one strain 
of a virus that prevents infection by a closely related sub-
strain of that virus. Serotype cross-over effects are an 
example of this. In Sweden, a direct comparison of the 
impact against IPD was performed in 21 counties who 
used either PCV10 or PCV13 vaccination. An increase 
in serotype 6C in the PCV10 counties was observed but 
not in the PCV13 counties. This was assumed to suggest 
that serotype 6A, which is included in PCV13 but not in 
PCV10, offers cross-protection against serotype 6C [28].
Finally, pathogens can induce side effects. A side 
effect refers to an effect, whether therapeutic or adverse, 
that is secondary to the one intended [29]. Although the 
term is predominantly employed to describe  adverse 
effects, it can also apply to unintended consequences of 
the use of a drug. An example of this is the Hemophilus 
influenzae type B (Hib) vaccination that by preventing 
bacterial infections from occurring or spreading pre-
vents infections and thus reduces the use of antibiotic 
treatment that would have been used to treat infections. 
Subsequently this reduces the development of secondary 
effects such as antimicrobial resistance [30].
Additional demand‑side consequences
The law of supply and demand is a theory that explains 
how the market allocates resources based on the 
interaction between the sellers of a resource and the buy-
ers of that resource [31]. The demand-side refers to the 
demand of goods and services which individuals want to 
buy or consume [32]. Previous frameworks have outlined 
the type of demand and supply constraints that may be 
considered in economic evaluations in health sector [33]. 
In terms of additional consequences, the type demand-
side, there are two categories related to health: Changes 
in health influencing behavior and changes in health ser-
vices consumption (both ‘internalities’).
Changes in health behavior and health services consump‑
tion Health behaviour refers to a person’s beliefs and 
actions regarding their health and well-being. An exam-
ple of a positive additional behaviour consequences was 
observed in Nepal, where changes in mothers’ behaviours 
and knowledge regarding hygiene and sanitation prac-
tices have been observed as a consequence of a universal 
immunisation programme which educates mothers about 
vaccination [34]. Health care consumption refers to the 
utilization of additional (or reduction in utilization of ) 
services by persons (‘internal’ person) for the purpose of 
preventing and curing health problems, promoting main-
tenance of health and well-being, or obtaining informa-
tion about one’s health status and prognosis. For example, 
following maternal tetanus vaccination in Bangladesh the 
consumption of health care services (‘internal’ person) 
was markedly reduced indicating a positive change in the 
need to seek health care services [35].
Additional supply‑side consequences
The supply-side refers to the part of the economy which 
involves the production of goods or supplying of services 
which are available to consumers or individuals [32]. 
For the type supply-side, we identify one category that 
fall under the health sector perspective: health systems 
(‘external’).
Health systems Providing an intervention can have many 
positive and negative spillovers in the health system. In 
addition, the direct opportunity cost of spending on inter-
ventions, the way they are delivered may influence the 
quality and delivery of other health services. For example, 
training provided as part of the scale-up of immunization 
programmes, may strengthen general clinical and non-
clinical skills, that may have positive benefits for the deliv-
ery of other services. A further example the benefits of 
influenza vaccination of healthcare workers is important 
for protecting staff and patients, for example previously 
influenza vaccinated healthcare providers demonstrated 
positive behavioral changes in their willingness to be vac-
cinated in forthcoming seasons thus generating additional 
benefit to the initial vaccination [36].
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Finally, in recent years there has been some attention 
to the potential, particularly of new interventions, to have 
spillover scientific benefits for the development of other 
health related technologies. For example, the knowledge 
of the mechanism of action associated with a new a drug 
or vaccine might offer value beyond itself and lead to 
later innovations in drug development or the treatment 
of very different diseases. The BCG vaccine exempli-
fies this by subsequent discovery resulting in treatment 
possibilities aside from those originally indicated (see 
Table 1).
Societal perspective
There is a wide literature of the possible non-health 
impacts of health interventions. These impacts can occur 
at the individual, household, and have follow-on conse-
quences for the sectoral and macro-level.
Demand‑side consequences
For the type demand-side, we highlight two broad cate-
gories: behavior/education/knowledge (‘internal’ person), 
and consumption of non-health goods.
Non‑health changes in behavior and consumption Health 
intervention can impact non-health related behaviors in 
many ways. One example is the impact on health on edu-
cation. Education is defined as the process of learning and 
acquisition of knowledge, skills, values, beliefs, and habits. 
An illustration of how immunization enhances learning 
and the acquisition of knowledge (education) ‘external’ to 
the individual originates from South Africa. The pneumo-
coccal conjugate vaccines have been associated with chil-
dren improving their educational attainment, due largely 
to the prevention of pneumococcal pneumonia [14]. 
Changes in educational attainment may have follow-on 
consequences for a wide range of behaviors that impact 
social welfare.
Health intervention can also result in changes of con-
sumption of non-health goods Households have reported 
negative changes in behaviours such as food consump-
tion and school attendance in children when a parent in 
the household has cervical cancer. This resulted in nega-
tive impact on educational attainment for children in the 
household which could have been prevented with the 
HPV vaccination [37].
Supply‑side consequences
For the type supply-side, we identify two categories that 
fall under the health consequences perspective: labor 
productivity (‘internal’ person) and provision of non-
health services.
Productivity Productivity impact is commonly captured 
in a societal perspective (although typically considered as 
a cost, rather than on the impact side of the incremental 
cost-effectiveness ration). In respect of immunization, the 
Hib vaccination has been demonstrated to increase moth-
ers’ productivity in the labor market [38]. Hib vaccination 
can reduce child mortality resulting in mothers of vacci-
nated children can achieve their target family size through 
fewer births. Having fewer children, may enable mothers 
to invest more resources in their own development which 
results in increased individual productivity (‘internal’ per-
son).
There may also changes in productivity in respect of 
informal labour. Informal care is generally defined as the 
unpaid care provided to older and dependent persons 
by a person with whom they have a social relationship, 
such as a spouse, parent, child, other relative, neighbour, 
friend or other non-kin [39]. An illustration of this comes 
from a Belgium study in which the caregiver burden 
within households in which children were not vaccinated 
against rotavirus was markedly severe; especially if no 
medical care was sought [40].
Non‑health sector service provision Non-health sector 
public service provision (‘external’) include areas like (e.g. 
public safety, infrastructure and social support services). 
An example of how immunization impacts services exter-
nal to the healthcare system is yearly influenza immuniza-
tion among the elderly. This reduces infection and related 
complications in the elderly and therefore results in 
reduced use of long-term social support systems outside 
the health care sector, such as institutional care in residen-
tial care home [41]. A simple checklist addresses (Table 2) 
how these categories of the effects of health technologies 
can be measured (tangible) or not (intangible) and what 
may condition their classification and inclusion into the 
economic evaluations.
Discussion and conclusion
We present a comprehensive framework to consider 
additional consequences. While there is other guidance, 
we bring this guidance together to assist analysts iden-
tify possible unintended consequences whether taking 
a provider or societal perspective. There is currently a 
rigorous debate around capturing the full value of health 
interventions both within and beyond the health sector. 
The intention of this paper is not to support the inclu-
sion of all additional consequences in every economic 
evaluation, but instead provide a framework to identify 
those that may be important. Moreover, any effects iden-
tified may not be additive in terms of overall value. Many 
of the effects listed interact (also with intended direct 
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health effect) and care should be taken to also identify 
any interactions, at the individual, household, sectoral or 
macro-level.
The consideration of additional effects can influence 
the analytic choice of health outcome measures used, 
and non-health outcome measures included. For exam-
ple, vaccine-induced improvements to immunity against 
non-targeted antigens (i.e. ‘internal’ person effects) mani-
fest in non-specific epidemiological health outcomes, 
such as for example all-cause acute gastroenteritis related 
hospitalizations that may not typically measure in vac-
cine trials.
In addition, it may impact other methodological 
choices. For example, if the framework identifies a poten-
tially major non-specific effect, it may be important to 
identify a comparator that also addresses that effect in 
the economic evaluation. For example, if the effect of 
the BCG vaccine extends beyond the protection against 
TB, and has substantial effects on auto-immune condi-
tions (e.g. atopic dermatitis in high risk infants) [42], an 
economic evaluation could consider comparing inter-
ventions or strategies beyond TB. Furthermore, the ana-
lytical choice of target population and subgroups for the 
economic evaluation may also change when considering 
non-direct effects. The additional effects of the BCG vac-
cine, as described above, may result in the comparison 
of the existing strategy of BCG vaccination to a strategy 
in which subgroups or risk groups who are not recom-
mended to receive the vaccine on grounds of risk of TB 
are included.
Applying this framework will not be without empiri-
cal challenges. Firstly, once potential additional conse-
quences are identified, their importance will need to be 
assessed. Determining when a consequence is sufficiently 
important is often challenging a priori and will be based 
on a mixture of prior evidence of plausible effect. Moreo-
ver, even where there is evidence from other populations, 
the data to parameterize additional consequences may 
not be available for the population being evaluated. Fur-
ther guidance is therefore required as to how to make the 
decision to include an additional consequence identified 
or when to simply report it qualitatively (as in the Second 
Panel impact inventory). While guidelines are clear that 
analyst should include all costs and effects relevant to the 
study perspective, practice on which are included varies 
substantially, which may lead to inconsistent decisions. 
Although there are many challenges ahead to standard-
ize the inclusion of additional consequences in economic 
evaluation, we hope by moving beyond generic state-
ments to reporting against a comprehensive framework 
of types and categories of additional effects we can sup-
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